NCT07064395 Bright Light Therapy on Sleep Health in Lung Cancer Patients
| NCT ID | NCT07064395 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Henry Ford Health System |
| Condition | Lung Cancers |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-06-09 |
| Primary Completion | 2026-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-06-09 with a primary completion date of 2026-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this randomized intervention trial is to determine the effect of bright light therapy on sleep disturbance, as well as to investigate the impacts of bright light therapy on biological age measured by clinical biomarkers. The main questions it aims to answer are: * Does bright light therapy improve sleep patterns (i.e., sleep onset latency, sleep disturbance, and sleep efficiency) in lung cancer patients? * Can bright light therapy slow the rate of aging measured by biological age in lung cancer patients? Researchers will compare bright light therapy group to control group to see if bright light works to reduce sleep disturbance and decelerate biological aging. Participants will: * Receive bright light exposure or usual light exposure every day for 4 weeks * Get blood draw at the baseline and at 4 weeks for clinical biomarkers tests * Complete self-reported sleep, fatigue and stress surveys at the baseline and at 4 weeks * Keep a daily sleep log
Eligibility Criteria
Inclusion Criteria: * \>=18 years of age * Stage Ib to IIIb primary lung cancer diagnosis * \>=2 months after completion of primary therapy, patient can continue to be on maintenance/immunotherapy * ECOG performance status is 0 or 1 * Experience problematic sleep (scores of \>=8 on the Insomnia Severity Index) * Able to understand, speak, and read English * Sighted and mentally competent to consent Exclusion Criteria: * Pregnant women * Have metastatic cancer * on oxygen therapy * Current diagnosis of seasonal affective disorder or substance abuse * Engage in shift work or travel across \>3 time zones within 2 weeks prior to the study * Are currently being treated for sleep apnea, restless legs syndrome, or narcolepsy * Take prescribed sedative hypnotics or antipsychotics * Have eye conditions (glaucoma or retinal disease), problem triggered by bright light (e.g., migraine), or take photosensitizing medications (e.g., some porphyrin drugs, antipsychotics, antiarrhythmic agents) * Participants with an Insomnia Severity Index \<8 * Participants with cognitive impairment (sores of \<3 mini-cog test)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07064395 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07064395 currently recruiting?
Yes, NCT07064395 is actively recruiting participants. Contact the research team at mtao1@hfhs.org for enrollment information.
Where is the NCT07064395 trial being conducted?
This trial is being conducted at Detroit, United States.
Who is sponsoring the NCT07064395 clinical trial?
NCT07064395 is sponsored by Henry Ford Health System. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.